Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Oncolytics Biotech in a ...
Investment analysts at HC Wainwright dropped their Q1 2025 earnings per share estimates for Cidara Therapeutics in a report ...
Fintel reports that on March 13, 2025, HC Wainwright & Co. initiated coverage of Perspective Therapeutics (NYSEAM:CATX) with ...
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
The establishment of a Strategic Bitcoin Reserve (SBR) in the U.S. is a "monumental endorsement" of the world's largest ...
Shares of Core Scientific Inc. (CORZ) gained almost 8% in Tuesday’s regular session and extended gains during after-hours ...
H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage ...
H.C. Wainwright analyst Scott Buck lowered the firm’s price target on AudioEye (AEYE) to $22 from $37 and keeps a Buy rating on the shares post ...
Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision ...
Plug Power (Nasdaq: PLUG). From a high north of $3, shares of the hydrogen pioneer have been cut roughly in half, falling as ...
Fintel reports that on March 7, 2025, HC Wainwright & Co. initiated coverage of Surf Air Mobility (NYSE:SRFM) with a Buy recommendation. As of March 4, 2025, the average one-year price target for ...
Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate ...